PharmaCyte Biotech (PMCB) Dividends payables (2023 - 2026)

PharmaCyte Biotech (PMCB) posted quarterly Dividends payables of $32491.0 for Q2 2026, little changed quarter-over-quarter from $32491.0 in Q1 2026.

PharmaCyte Biotech (PMCB) Dividends payables (2023 - 2026) Analysis & Trends

PharmaCyte Biotech (PMCB) has reported Dividends payables for 4 consecutive years, with $32491.0 the latest figure, recorded in Q2 2026.

In Q2 2026, Dividends payables changed N/A year-over-year to $32491.0; the TTM figure through Apr 2026 stood at $32491.0 (changed N/A YoY), while the FY2026 annual figure was $32491.0, changed N/A from the prior year.
Dividends payables held at $32491.0 in Q2 2026 per PMCB's latest filing, from $32491.0 in the prior quarter.
Across five years, Dividends payables topped out at $6.3 million in Q2 2024 and bottomed at $32491.0 in Q1 2026.
Historically, Dividends payables has averaged $3.0 million across 4 years, with a median of $3.7 million in 2024.
Annual changes were most pronounced in 2024 — Dividends payables soared 1849.31% — and 2025, when it plunged 99.05%.
PharmaCyte Biotech's Dividends payables stood at $4.1 million in 2023, then fell by 9.15% to $3.7 million in 2024, then slumped by 99.05% to $35389.0 in 2025, then dropped by 8.19% to $32491.0 in 2026.
Business Quant data shows PMCB's Dividends payables at $32491.0 in Q2 2026, $32491.0 in Q1 2026, and $35389.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Dividends payables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	PharmaCyte Biotech	4.38 Mn	4.38 Mn	-	32,491.00

Download Data